Protagonist Therapeutics Inc FY2025 Q2 Net Loss Increased 13.7% Compared to Prior Year

Executive Summary

Protagonist Therapeutics Inc (PTGX) reported its financial results for the second quarter of fiscal year 2025, showing a net loss of $46.4 million, which is a 13.7% increase compared to the net loss of $40.8 million in the same period last year. The company’s total assets decreased slightly by 3.6%, primarily driven by a reduction in marketable securities. Cash and cash equivalents stood at $168.5 million, reflecting a decrease of 53.2% from $359.0 million in the prior year, mainly due to ongoing R&D investments and operational expenses. Revenue for the quarter was $5.5 million, up 32.4% YoY, driven by collaboration and license revenues. The company continues to focus on advancing its clinical pipeline, with significant milestones expected in the upcoming periods, including potential NDA filings and regulatory approvals.

Key Metrics

Management Discussion and Analysis

Protagonist Therapeutics’ second quarter of 2025 reflects continued investment in its innovative pipeline, with R&D expenses rising to $37.0 million from $33.5 million YoY, representing a 10.4% increase. The company’s collaboration revenue increased to $5.5 million from $4.2 million, primarily due to milestone achievements and licensing agreements, notably with Johnson & Johnson and Takeda. Operating expenses also increased, with general and administrative costs rising modestly to $10.5 million from $9.4 million. The net loss widened, primarily due to increased R&D and operational costs, but the company remains committed to advancing its clinical programs, including the submission of an NDA for icotrokinra and ongoing rusfertide trials. Cash burn was significant, with net cash used in operating activities totaling $96.6 million, emphasizing the need for strategic capital management and potential future financings.

Income Statement Analysis

Revenue for Q2 FY2025 increased by 32.4% YoY, driven by collaboration and license agreements, notably with J&J and Takeda, totaling $5.5 million. R&D expenses rose by 10.4%, reflecting ongoing clinical trial activities and pipeline development. General and administrative expenses increased slightly, indicating scaling of corporate infrastructure. The net loss expanded to $46.4 million from $40.8 million YoY, with EPS of -$0.73 on a basic basis. The gross margin is not explicitly provided but is implied to be low given the early-stage nature of the company’s revenue streams. The company expects to incur further losses as it invests in clinical development and potential commercialization efforts.

Balance Sheet Analysis

As of June 30, 2025, Protagonist held $168.5 million in cash and cash equivalents, down from $359.0 million at the end of 2024. Total assets declined slightly to $718.0 million from $744.7 million, mainly due to a reduction in marketable securities from $321.7 million to $102.5 million. Receivables from collaboration partners decreased to $165.0 million from $165.0 million, reflecting ongoing milestone payments. Total liabilities decreased to $50.0 million from $69.4 million, primarily due to the settlement of payables and deferred revenue. Stockholders’ equity stood at $668.0 million, with an accumulated deficit of $387.0 million, indicating ongoing R&D investments without profitability yet. Liquidity remains adequate for near-term operations, but the company must manage its cash burn carefully.

Cash Flow Analysis

Net cash used in operating activities was $96.6 million for the quarter, primarily due to net losses and increased R&D spending. Investing activities included the purchase of $0.3 million in property and equipment and the net sale of $7.0 million of marketable securities, resulting in a net cash outflow of $39.6 million. Financing activities generated $14.4 million, mainly from the issuance of common stock and stock options. Overall, cash and cash equivalents decreased by $191.0 million during the period, leaving a balance of $168.5 million, which is sufficient to fund operations into the next 12 months under current expenditure levels.

Ratios & DuPont Analysis

Protagonist’s net profit margin remains negative at -842%, reflecting ongoing losses. Return on assets (ROA) is -6.4%, and return on equity (ROE) is -6.9%, indicating high investment in R&D with no current profitability. Asset turnover is approximately 0.01, showing low revenue relative to total assets. The equity multiplier is 1.07, suggesting modest leverage. The company’s financial profile underscores the early-stage nature of its business, with significant investment risk but potential for future value creation upon successful clinical and regulatory milestones.

Risk Factors

Key risks include regulatory delays or denials, market competition from established biologics and emerging therapies, operational risks related to clinical trial execution, and financial risks due to high cash burn and need for future capital raises. Macro risks such as economic downturns and changes in healthcare policies could impact funding and commercialization prospects. The company’s reliance on collaboration milestones and licensing revenues also introduces dependency risks.

Notes & Additional Commentary

Significant one-time events include the receipt of a $165 million milestone payment from J&J in late 2024 and a $300 million upfront payment from Takeda in early 2024. The company’s pipeline progress, including the NDA submission for icotrokinra, is a critical catalyst. The increase in net loss reflects ongoing R&D investments, with no material revenue from product sales yet. The company’s strategic focus remains on advancing clinical programs toward regulatory approval, which could substantially alter its financial trajectory.

Investment Implications

Protagonist Therapeutics presents a high-risk, high-reward profile typical of biotech firms in clinical development. Near-term opportunities include milestone achievements and potential NDA filings, which could trigger significant valuation re-ratings. Long-term risks involve clinical trial failures, regulatory setbacks, and funding challenges. Investors should weigh the promising pipeline and recent milestone payments against the substantial cash burn and lack of profitability. A balanced approach with close monitoring of clinical progress and capital needs is recommended.